We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+53.73%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$165M
AUM Growth
–
Cap. Flow
+$142M
Cap. Flow %
86.11%
Top 10 Hldgs %
92.81%
Holding
15
New
15
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$22.4M
2
ZGNX
Zogenix, Inc.
ZGNX
+$21.4M
3
INSM icon
Insmed
INSM
+$20.1M
4
AMRN
Amarin Corp
AMRN
+$16M
5
ALLK
Allakos
ALLK
+$11.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$24.3M 14.75%
+466,875
New +$21.4M
INSM icon
2
Insmed
INSM
$23.5B
$23.6M 14.31%
+988,999
New +$20.1M
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.38B
$22.1M 13.37%
+515,788
New +$22.4M
AMRN
4
Amarin Corp
AMRN
$292M
$18M 10.94%
+42,086
New +$16M
IOVA icon
5
Iovance Biotherapeutics
IOVA
$2.23B
$12.6M 7.62%
+453,890
New +$10.3M
ARGX icon
6
argenx
ARGX
$53.8B
$12.5M 7.6%
+78,138
New +$10.6M
ALLK
7
DELISTED
Allakos
ALLK
$12.3M 7.44%
+128,662
New +$11.3M
ENTA icon
8
Enanta Pharmaceuticals
ENTA
$400M
$10M 6.06%
+161,949
New +$10M
NGNE icon
9
Neurogene
NGNE
$744M
$9.98M 6.05%
+40,504
New +$4.03M
KPTI icon
10
Karyopharm Therapeutics
KPTI
$216M
$7.7M 4.67%
+26,774
New +$5.81M
ASND icon
11
Ascendis Pharma A/S
ASND
$17.1B
$4.13M 2.5%
+29,676
New +$3.3M
ACHN
12
DELISTED
Achillion Pharmaceuticals
ACHN
$3.77M 2.28%
+624,956
New +$3.62M
XENT
13
DELISTED
Intersect ENT, Inc
XENT
$2M 1.21%
+80,238
New +$1.63M
KNSA icon
14
Kiniksa Pharmaceuticals
KNSA
$4.92B
$1.83M 1.11%
+165,318
New +$1.44M
TARA icon
15
Protara Therapeutics
TARA
$230M
$140K 0.08%
+8,544
New +$98K

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Fairmount Funds Management, which disclosed 15 positions worth $165M. Its ten largest holdings account for 93% of the portfolio.

Its largest position is Acadia Pharmaceuticals: 515,788 shares worth $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets.

  • Fairmount Funds Management's largest Q4 2019 buy was Acadia Pharmaceuticals: 515,788 shares worth $22.1M.
  • Fairmount Funds Management's ten largest holdings make up 93% of its $165M portfolio in Q4 2019.
  • Fairmount Funds Management disclosed 15 positions in Q4 2019, its first 13F filing on record.

Based on Fairmount Funds Management's 13F filing for Q4 2019, filed 12 Feb 2020.